Browsing Tag
MedinCell
5 posts
Can Elisabeth Svanberg help Medincell turn clinical progress into durable value?
Medincell wants pharmaceutical executive Elisabeth Svanberg to join its board and lead its remuneration and nomination committee. The proposal comes as the French biotechnology company moves from platform development towards recurring royalty growth and potential multi-product commercialisation.
Why Teva’s once-monthly olanzapine shot could finally change how schizophrenia is treated in the U.S.
Find out how Teva’s FDA-accepted once-monthly olanzapine injection could reshape schizophrenia care and what investors and clinicians will watch next.
Teva’s new bipolar breakthrough: FDA clears UZEDY as the first monthly long-acting risperidone
Teva’s UZEDY long-acting injectable gains FDA approval for bipolar I maintenance, reshaping psychiatric treatment and investor sentiment.
Medincell’s Phase 3 trial for long-acting injectable olanzapine in schizophrenia reaches completion
Medincell has announced the successful completion of the pivotal Phase 3 SOLARIS clinical trial for its long-acting injectable…
Teva Pharmaceuticals, MedinCell get UZEDY FDA approval for schizophrenia
Teva Pharmaceuticals and MedinCell have bagged approval for UZEDY (risperidone) extended-release injectable suspension from the US Food and…